Durability of ChAdOx1 nCov-19 vaccination in people living with HIV

Duration of protection from SARS-CoV-2 infection in people with HIV (PWH) following vaccination is unclear. In a sub-study of the phase 2/3 the COV002 trial (NCT04400838), 54 HIV positive male participants on antiretroviral therapy (undetectable viral loads, CD4+ T cells >350 cells/ul) receiv...

Full description

Bibliographic Details
Main Authors:	Ogbe, A, Pace, M, Bittaye, M, Tipoe, T, Adele, S, Alagaratnam, J, Aley, PK, Ansari, MA, Bara, A, Broadhead, S, Brown, A, Brown, H, Cappuccini, F, Cinardo, P, Dejnirattisai, W, Ewer, K, Fok, H, Folegatti, PM, Fowler, J, Godfrey, L, Goodman, AL, Jackson, B, Jenkin, D, Jones, M, Longet, S, Makinson, RA, Marchevsky, NG, Mathew, M, Mazzella, A, Mujadidi, YF, Parolini, L, Petersen, C, Plested, E, Pollock, K, Rajeswaran, T, Ramasamy, MN, Rhead, S, Robinson, H, Robinson, N, Sanders, H, Serrano Fandos, S, Tipton, T, Waters, A, Zacharopoulou, P, Barnes, E, Dunachie, S, Goulder, P, Klenerman, P, Screaton, GR, Winston, A, Gilbert, SC, Pollard, AJ, Lambe, T, Frater, J
Format:	Journal article
Language:	English
Published:	American Society for Clinical Investigation 2022

Durability of ChAdOx1 nCov-19 vaccination in people living with HIV

Similar Items